Search results
Dengvaxia ®, Sanofi’s tetravalent live attenuated vaccine against dengue fever, received its first marketing authorizations in 2015 and is currently approved for use in the US, EU and in some Asian and Latin American countries. 1,2,3.
Dengue is an outbreak-prone, unpredictable disease with a first infection raising the risks that subsequent infections may become severe. It's transmitted by mosquitoes, so multiple factors, including urbanization, water storage practices and vector control measures can impact the risk for dengue-endemic communities. 3.
May 17, 2021 · Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV), manufactured by Sanofi Pasteur (Paris, France), and is the first and only of its kind that has been licensed for use in 19 countries, but is only available in 10. 2 Several phase II and phase III studies have led to particular ...
May 10, 2024 · Two dengue vaccines have been licensed, Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur, and Qdenga® (TAK-003), developed by Takeda. Another dengue vaccine developed at the Laboratory of Infectious Diseases, at the National Institutes of Allergy and Infectious Diseases (NIAID) in the United States, is in the late stages of ...
Nov 29, 2016 · Based on the new analysis, Sanofi will propose that national regulatory agencies update the prescribing information, known as the label in many countries, requesting that healthcare professionals assess the likelihood of prior dengue infection in an individual before vaccinating.
Apr 15, 2023 · Dengvaxia® Sanofi Pasteur licensed the first dengue vaccine (Dengvaxia®) in Mexico in 2015, and more than 20 countries thereafter, based on the safety and efficacy demonstrated in two phase...
Dengvaxia is a live, attenuated vaccine that is administered as three separate injections, with the initial dose followed by two additional shots given six and twelve months later.
